Study of AZD8965 for people with IPF
Part of Lungs & breathing clinical trials.
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 40 years old.
- You have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF).
- You are either on a stable dose of an approved IPF treatment or not receiving standard care.
- Your lung function tests show FVC is at least 45% of predicted normal.
- Your DLCO (a measure of gas exchange) is at least 25% of predicted normal after adjusting for hemoglobin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study tests a new medicine called AGMB-447 for people with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred and breathing becomes harder. The goal is to see if the treatment is safe and helps improve lung function.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.